Rapidly evolving genome technology has enabled extensive molecular analysis of limited tumor biopsy material, thereby facilitating the broader implementation of personalized cancer medicine. However, genomics-based patient stratification across diverse tumor types is unlikely to supplant tissue-of-origin considerations in addressing clinical needs, including the development and application of novel ''rationally targeted'' cancer therapies.
Discovery and translational research conducted during the past 30 years has led to the identification and validation of a number of ''cancer drivers''-genes that, when mutated or otherwise dysregulated, can drive malignancy in model systems. Several treatments that directly target such drivers have yielded unprecedented activity in early-stage clinical trials, resulting in relatively rapid regulatory approval. These approvals have typically referenced diagnostic tests performed on tumor tissue to indicate the presence of a biomarker that predicts response. Thus, for example, the HER2-targeted antibody trastuzumab is approved for use in breast cancer patients whose tumors exhibit overexpression of HER2 as demonstrated by fluorescence in situ hybridization (FISH) or immunohistochemistry (Figueroa-Magalhaes et al., 2013) . A more recent example is the BRAF kinase inhibitor vemurafenib, which is approved for treatment of metastatic melanomas that harbor a particular activating BRAF mutation in the tumor DNA (Chapman et al., 2011) , and there are now additional examples of successful clinical implementation of biomarker-guided cancer treatmentsparticularly with inhibitors of the various oncogenic kinases. Consequently, the number of patients for whom such genomic information is available at some point in their disease course is rapidly increasing.
Technologies for genomic profiling of tumors have rapidly evolved over the past decade. Early efforts to profile tumor DNA involved single-nucleotide polymorphism (SNP) mapping and comparative genomic hybridization (CGH) to describe segmental gains or losses of DNA, as well as rearrangements. More recently, genomic analysis has focused on mutation identification via resequencing of either a limited set of genes, whole exomes, or whole genomes. In addition, advances in RNA-based technologies, including improved expression arrays and RNA sequencing, have provided more accurate gene expression profiles that have proven particularly useful for tumor classification and prognostication in several anatomic sites and for tissue-of-origin assessment in cases of carcinomas of unknown primary origin (Monzon et al., 2009) . Efforts to profile the tumor ''epigenome'' have also been intensifying. A variety of genome-wide assessments of DNA methylation, histone modification, and transcription factor occupancy on DNA have now been described, though none have been widely used clinically thus far.
In considering the case for genomicsbased patient stratification in the following discussion, our goal is to address the question of whether tissue-of-originbased classification is likely to remain relevant in the face of an increasingly ''genome-centric'' view of human tumors. We see two key considerations. First, how can patient-specific genomic profiling be optimally used to guide clinical care and thus realize the vision of ''precision oncology'' (Garraway et al., 2013) ? Second, should tumors still be classified on the basis of tissue-of-origin, or should revamped classification based on genomic features be substituted? In the analysis and recommendations that follow, we consider the lessons learned from the initial wave of ''rationally targeted'' therapies in light of current trends. We offer a perspective on the emerging use of tumor genome information to accelerate the clinical development of novel agents and to optimize the use of current therapeutics.
Early oncogene discovery efforts were largely focused on identifying dominantly acting, mutated genes that are capable of transforming cells to a malignant state as a means of elucidating potential cancer drivers. Transformation assays that were, in retrospect, extremely sensitive to mutationally activated Ras and various signal-transducing kinases, for example, quickly revealed that activating oncogenic mutations are relatively common in human cancers and implicated the corresponding oncoproteins as targets for rational therapy. Perhaps the most compelling clinical data resulting from such work was the demonstration in phase I studies that the ABL kinase inhibitor imatinib exhibited unprecedented activity in advanced cases of chronic myelogenous leukemia (CML), a disease in which virtually every case is characterized by an oncogenic rearrangement of the Abl gene (Druker et al., 2001a (Druker et al., , 2001b . The imatinib experience in CML proved the principle that remarkable clinical benefit could be achieved by directly targeting mutationally activated oncoproteins. Similar subsequent experience with other targeted agents further supported this paradigm-as exemplified by the dramatic activity of EGFR and ALK kinase inhibitors in EGFR mutant and ALK-rearranged lung cancers, respectively (Minuti et al., 2013) .
The feasibility of genomically guided clinical trial design is now well established. In several tumor types, oncogenic mutations have been reliably identified by sequencing tumor-derived DNA, and mutation-positive patients have been subsequently evaluated for their response to targeted agents in clinical trials. For example, the EURTAC study of the EGFR inhibitor erlotinib as initial treatment enrolled patients with EGFR mutant metastatic lung cancer. Gratifyingly, the study was positive at an early interim evaluation point (Rosell et al., 2012) . Randomization was stopped after only 174 patients were enrolled when interim data revealed that patients treated with erlotinib lived twice as long without disease progression compared to those treated with chemotherapy. These dramatic results were obtained more than 5 years after erlotinib's initial approval for non-small cell lung cancer, which was granted without regard to EGFR status. In that pivotal study, more than 700 patients were randomized, and the effect on progressionfree survival was much more modest (2.2 months versus 1.8 months with chemotherapy). Clearly, genomic information can be useful in guiding the successful development of novel targeted agents.
Clinical researchers have come to expect ''breakthrough efficacy'' as the hallmark of an agent effectively targeting a tumor driver. Indeed, revisions to clinical trial methodology to facilitate early approval of particularly active agents have been proposed by a number of groups, including patient advocacy organizations (Horning et al., 2013; Mullins et al., 2012) . Moreover, the relatively recently acquired ability to collect wholegenome expression profiles and deep DNA sequence information from small amounts of tumor biopsy material has provided an opportunity to greatly expand the use of molecular profiling in guiding drug development and treatment decisions. However, as described below, additional context is required to make optimal use of this information.
Paralleling these key discoveries supporting the ''oncogene addiction'' paradigm and the consequent potential for personalizing cancer drug therapy, increasingly comprehensive tumor genome analysis has revealed that similar activating mutations are present in tumors derived from different tissue types, pointing to potential common therapeutic vulnerabilities among tumors of distinct origin. Results of early attempts to generalize the use of targeted agents across histologically distinct cancers following initial proof of concept in a given tumor type have been mixed. Recent experience with BRAF-targeted agents in patients with the identical activating BRAF mutation provides a case in point and suggests that tissue context may indeed be an important determinant of treatment response. V600E or similarly activating BRAF mutations are seen in 5%-8% of colorectal cancers, 30%-70% of papillary thyroid tumors, and a smaller fraction of tumors derived from lung, brain, and various other tissues (http://cancer. sanger.ac.uk/cosmic/gene/analysis?ln= BRAF#dist). Although vemurafenib is highly active in the treatment of melanomas harboring the V600E mutation, clinical studies of vemurafenib in BRAF mutant colorectal cancer have been disappointing thus far, and recent findings implicate EGFR signaling in bypassing a strict dependency on activated BRAF in this setting (Corcoran et al., 2012; Prahallad et al., 2012 ). The precise role of BRAF in other settings where it undergoes mutational activation is even less clear. The BRAF experience thus far suggests that relatively low mutation frequencies across a diverse range of histologic tumor types will present major obstacles to the clinical evaluation of targeted treatments. In addition, tissue context clearly affects the prognostic impact of driver mutations, with examples provided by the variable effects reported for KRAS, EGFR, and BRAF mutations among tumors of the lung and colon (Bauml et al., 2013; Custodio and Feliu, 2013) .
Recently, so-called ''basket'' studies have been proposed to facilitate the development of novel targeted anticancer agents (Willyard, 2013) . In this trial design paradigm, patients with disparate tumors (derived from distinct tissue types) are eligible for similar treatment if their tumor harbors a pre-specified genetic lesion. Basket designs may be particularly appealing when either the genetic lesion or the particular tumor types (or both) are relatively rare. However, grouping patients in this way is cumbersome and runs the risk of failing to address practical disease-management needs. As an obvious example, integrated cancer care includes consideration of local therapies in addition to systemic ones and often involves surgeons, oncologists, and radiotherapists who specialize in a particular tissue type or organ system.
The challenges for clinical research and drug development created by the presence of relatively low-frequency driver mutations distributed across a variety of tumor types have prompted consideration of whether genomic analysis of tumor biopsies should be applied more broadly or should even replace traditional histology-based diagnosis of cancer. The data for BRAF and other oncogenes suggest that the notion that a ''driver'' mutation behaves similarly across tumor contexts may be invalid, yet this is a critical assumption underlying the rationale for driver-based classification. We believe that the biology of each putative driver must be addressed in specific tissuedefined disease contexts to establish a compelling scientific rationale for using molecular classification as the dominant criterion for patient stratification. Currently, the focus of pathologic disease classification remains decidedly on anatomic tissue of origin. But traditional pathologic classification can respond quickly to important new information. Thus, elucidation of HER2 biology and the availability of effective anti-HER2 treatments led to the inclusion of ''HER2 positive'' as an important classification parameter carrying prognostic information as well as offering the potential to guide treatment (Sauter et al., 2009) .
A more elaborate example is provided by the clinical experience with precursor B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood tumor. Over the past 30 years, hematopathologists grappled first with new information about cell surface markers on various leukemias and, more recently, with cytogenetic, genetic, and epigenetic information derived from a large number of cases. Although histologic assessment has diminished somewhat in importance, the result has been a tremendously valuable classification scheme based on an amalgamation of this information (Mullighan, 2012) . Currently, 10-12 types of B-ALL are recognized, with frequencies ranging from 1%-30%. Classification on this basis provides predictive information about the efficacy of high-dose conventional chemotherapy and that of newer targeted treatments, as well as valuable prognostic information.
In light of such examples, at present there seems to be little to be gained from a substantial effort to reclassify tumors on the basis of molecular phenotype, irrespective of the site of origin. The effort required for such a conceptual change would be large and the payoff uncertain. Variable driver effects across tumor types would likely limit both the value and utility of the resulting classification system. However, regardless of the potential need to revise the basis for pathologic tumor classification, the rationale for routinely including tumor genomic analysis as part of a pathology report seems compelling. The number of targeted investigational agents is increasing rapidly, and regulatory approval mandates the performance of a ''companion'' diagnostic test in many cases. Consequently, DNA-based diagnostic assays have begun to be performed routinely in the clinical pathology setting. It is essential that such information is provided in the medical record, given its emerging value in clinical decision making. As examples, consider the FDA approvals of the BRAF inhibitors dabrafenib and vemurafenib. Both were granted an identical indication as follows: ''indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDAapproved test.'' These indication statements frame important issues in the future development and rational application of precision oncologic treatments: if only a subset of patients is expected to benefit, how should appropriate patients be identified? Will regulatory authorities (and, ultimately, payers) continue to require specific, dedicated diagnostic tests, i.e., ''companion diagnostics,'' before a product can be used? Or, will the easy availability and decreasing cost of broad-based tumor sequence data supplant the need for future ''one-off'' companion diagnostics? Although the routine clinical generation of ''actionable'' cancer genomic information is in its relative infancy, it is clear that pathologists and clinicians will inevitably need to confront the implications of a much more data-rich future.
It is instructive to consider the emerging experience with tumor sequencing for identification of driver mutations in the context of successful classification systems such as those used in the leukemias. In leukemia classification, as mentioned above, a variety of approaches have proven useful. Cell phenotyping by FACS, cytogenetics, and gene expression profiling can stratify leukemias into robust subgroups manifesting different behaviors across studies. Upon more detailed genomic profiling, many of these subgroups demonstrate an enrichment for specific mutations and epigenetic patterns (Miller et al., 2013) . These, in turn, demonstrate unique responses to conventional and targeted therapies, as well as distinct clinical behaviors.
It is increasingly critical that future tumor classification approaches enable reliable prediction of response to targeted agents such as kinase inhibitors. As an example, after demonstrating safety in a phase 1 clinical study, the multikinase inhibitor sorafenib was evaluated in a broad-based phase 2 trial that ultimately included more than 500 patients (Eisen et al., 2006) . Eventual regulatory approval in renal cell cancer was based on the results from a phase 3 study of almost 1,000 patients with no molecular selection criteria (Escudier et al., 2007) . Another 1,000 patients were studied to gain subsequent approvals in hepatocellular carcinoma and thyroid cancer, again without molecular selection criteria (Iyer et al., 2010) . Although the activity of sorafenib in certain clinical situations is unequivocal, the failure to identify responsive subpopulations in studies involving more than 2,500 patients is disappointing for a putative targeted agent. It is even possible that the clinical benefit associated with sorafenib treatment reflects an anti-angiogenic activity resulting from VEGF receptor inhibition, which would probably not be revealed through tumor genome analysis (Heng and Bukowski, 2008) .
The recently proposed basket trial design offers a number of advantages in surveying potentially responsive tumors, including the opportunity to study the feasibility of obtaining comprehensive genomic and epigenetic profiles for all patients. Examples of genetic driver lesions appropriate for such designs include the genomic activation of ALK in some anaplastic lymphomas, neuroblastomas, and lung cancers, as well as the spectrum of BRAF mutant and PIK3CA (PI3 kinase) mutant tumors, which have been associated with diverse tumor types (Eifert and Powers, 2012) . Although regulatory agencies are unlikely to accept small numbers of patients as a basis for approval, such studies can flexibly expand patient numbers in responsive populations to increase the confidence in any observed signals. For relatively rare diseases in which the need for new treatments is great and options are limited, such data may be sufficient to support additional indications for previously approved agents. However, basket trials may present significant risk in the context of a primary approval focused on a particular genetic lesion rather than a given tumor type because there is no certainty of a consistent therapeutic effect across tumor types. Indeed, the net outcome of such studies could be the ''dilution'' of an important treatment benefit, as experience to date suggests that tissue-specific effects are common (Dancey et al., 2012) . Thus, the sample size requirement for basket trials might be many times larger than a more focused trial in order to provide sufficient statistical power for informative subgroup analysis.
Accumulating experience suggests that comprehensive profiling within a given tumor type is most likely to provide a solid basis for useful classification. By integrating expression, sequence, and epigenetic information, it is reasonable to expect that robust subtypes can be identified, as has been the case for the leukemias. A particularly acute need is epigenomic profiling. Previous assays have been extremely cumbersome and have produced limited patient-specific information. Despite this, both histone deacetylase inhibitors and DNA-demethylating agents have been approved for limited indications. However, the potential utility of such agents in broad tumor populations is largely unknown. Simpler sequence-based methods for epigenetic profiling have recently been described (Buenrostro et al., 2013) , and such approaches may provide essential information to help predict the clinical utility of epigenetic modifiers in broader disease contexts.
Nascent efforts are underway to establish the feasibility of performing comprehensive tumor genetic profiling, including deep sequencing, in clinical trials. Large profiling efforts such as the NCI's proposed 1,000 patient MATCH program seek to incorporate this information into clinical decision making . A series of comparative phase 2 studies would then compare novel treatment approaches with standard therapies in well-defined patient populations. The study design is necessarily complex, and implementation is expected to be challenging. However, the potential reward in rapidly correlating response with genomic information in appropriate patient populations seems compelling.
We believe that these profiling efforts can and should be accelerated to maximize the potential utility of dozens of targeted agents, both approved and in development. As an initial step, we propose a minimum strategy of annotating routine pathologic information with detailed sequence information from a set of several hundred genes, including cancer drivers and others with actionable mutations. Such a data set has the potential to address a number of worthwhile objectives simultaneously. First and most importantly, the unique data generated would enable clinical decision making for individual patients, particularly those with advanced disease and limited options. Second, the data would provide correlative genetic information to evaluate the performance of companion diagnostics. Third, such an approach would provide abundant opportunities for pilot studies to address issues related to specimen collection and processing, data quality, data storage, reporting to clinicians and patients, data sharing for research, and costs.
A key aspect of this proposed approach is that it creates an opportunity to leverage the value of genomic profiling of individual patients by identifying and collecting cases characterized by unusual efficacy of a targeted agent, particularly cases outside of approved treatment indications. In this way, emerging clinical experience can be brought to bear on the question of whether a given mutation is likely to be a cancer driver in a particular cancer type. Ongoing broad-based tumor sequencing efforts can be leveraged as well. For example, in 2011, BRAF V600E mutations were identified in 48 out of 48 patients with classic hairy cell leukemia (HCL) (Tiacci et al., 2011 ), a relatively rare disease, and subsequent case reports have documented responses to vemurafenib in refractory HCL (Dietrich et al., 2012) .
As illustrated by the experience with BRAF V600E mutations in hairy cell leukemia, a very small number of informative cases could be sufficient to advance clinical drug research in promising areas. The result could be more focused and parsimonious oncology drug development accompanied, when necessary, by limited changes in disease classification to accommodate emerging information. Sponsors and regulatory agencies would rapidly gain information to allow approval-seeking studies, information that would be particularly valuable in rare indications. Because the most informative responses typically occur in the context of single-agent treatment, oncologists and others should be trained and incentivized to report to regulatory agencies unusually complete or durable responses to single agents, particularly those observed with a targeted agent in the setting of otherwise refractory disease. More efficient reporting of well-annotated cases in the future, coupled with clinical trial innovations, such as the flexible and adaptable basket design, will accelerate the routine practice of precision oncology.
We base the idea of ''mining'' emerging clinical experience to capture unusual responses in genomically annotated cases on the established principles of safety pharmacovigilance to detect unusual or infrequent toxicities, as currently practiced by the FDA and other regulatory agencies. Though various aspects of pharmacovigilance have been criticized, broad-based reporting of serious adverse events, typically including a defined set of clinical information, remains routine. In many cases, adverse event reporting has allowed prompt regulatory action to protect public health (Crowther, 2013) . We believe that the availability of targeted agents, together with relevant tumorderived genomic information, enhances the opportunity for precision oncology, and we look to regulatory agencies for elaboration of ''precision approval'' paths necessary to realize this vision. A key first step is to create a simple system for efficacy reporting with sufficient incentives to ensure broad-based sampling of the emerging clinical experience. Regulatory authorities should enforce phase 4 commitments as a condition of approval to provide significant incentives (and opportunities) for the sponsor of a new drug. An example would be a requirement for drug sponsors to monitor off-label experience by providing genomic profiling for treated patients and for collecting essential follow up information. National health systems and payers have obvious incentives to direct the use of expensive targeted agents to the patients most likely to benefit.
That the pursuit of better treatment for cancer patients will be greatly aided by comprehensive genomic profiling seems inarguable. Using this information together with an ever-increasing arsenal of rationally targeted agents will provide unprecedented opportunities to match the right patient with the right treatment, ultimately improving outcomes for many. But translation from genetic lesions to effective cancer treatments has proven that tissue context matters critically. Moreover, the relative contributions of the genomic profile and the specific tissue context to the clinical response are likely to be drug specific and, to a large degree, will need to be empirically determined through rigorous clinical evaluation. Omnibus attempts to reclassify cancers across tissues according to their genetic defects are premature. Given this reality, continued efforts to refine clinical trial designs to accommodate genomic and epigenetic profiling represent a more urgent need.
